Abstract:Background Radioresistance of thoracic radiotherapy is a major bottleneck in the treatment of non-small cell lung cancer (NSCLC). Until now, there have been no effective biomarkers to predict the radiosensitivity. Purposes Based on miRNA profile screened from NSCLC cell lines with different radiosensitivity, this study was conducted to explore the correlation between plasma miRNAs and radiotherapy response in NSCLC patients, and to identify biomarkers of the radiosensitivity in NSCLC. Methods Differentially expressed genes were acquired from time-series gene expression profiles of radioresistant H1299 and radiosensitive H460 lung cancer cells (GSE20549). Potential miRNAs were screened from these differentially expressed genes by combining bioinformatics with GO analysis, pathway analysis, and miRNA prediction. A clinical observational study was performed to explore the correlation between candidate miRNAs and radiotherapy response. Stage IIIa–IV NSCLC patients who received two to four cycles of previous chemotherapy and underwent thoracic radiotherapy alone were included. Total RNA was purified from peripheral blood before radiotherapy, and plasma miRNAs were detected by real-time PCR (qRT-PCR). Then, tumor response, progression-free survival (PFS), and overall survival (OS) were acquired. Four miRNAs significantly different between effective and ineffective groups were further analyzed to obtain cutpoints from receiver operating characteristic (ROC) curves and the predictive value of radiosensitivity. Results Candidate miRNAs included 14 miRNAs screened from radioresistant genes and five from radiosensitive genes. From Jan., 2013 to Dec., 2014, 54 eligible patients were enrolled with a median follow-up of 15.3 months (range 4.6 to 31.4) by the deadline of Aug. 31, 2015. Totally, there were no case of complete response (CR), 15 of partial response (PR), 35 of stable disease (SD), and 4 of progressive disease (PD). Eight patients had no progression and 19 patients were still alive. The median PFS and OS were 6.6 months (range 2.3 to 29.3) and 15.3 months (range 4.6 to 31.4), respectively. Four miRNAs (hsa-miR-98-5p, hsa-miR-302e, hsa-miR-495-3p, and hsa-miR-613) demonstrated a higher expression in effective group (CR + PR, 15 cases) than in ineffective group (SD + PD, 39 cases). Based on each cutpoint, objective response rate (ORR) was higher in miR-high group than in miR-low group. No miRNA showed correlation with median PFS or OS. Conclusion Bioinformatical analysis and clinical verification reveal the correlation between plasma miRNAs and radiosensitivity in NSCLC patients. Plasma miRNAs represent novel biomarkers to predict radiotherapy response clinically.

Plasma Micrornas Predict Chemoresistance in Patients with Metastatic Breast Cancer.

Plasma miRNA expression could predict clinicopathological characteristics and chemosensitivity in patients with metastatic breast cancer

Plasma miR-221 as a predictive biomarker for chemoresistance in breast cancer patients who previously received neoadjuvant chemotherapy.

Predicting distant metastasis and chemoresistance using plasma miRNAs

Circulating Micrornas As Specific Biomarkers for Breast Cancer Detection

Non-invasive Microrna Signatures from the Plasma of Breast Cancer Patients Reveals Sensitive and Specific Marker for Breast Cancer Screening

Plasma miRNAs in predicting radiosensitivity in non-small cell lung cancer

Identification of Mirna Signature in Breast Cancer to Predict Neoadjuvant Chemotherapy Response

Plasma Exosomal miRNA Expression Profile as Oxaliplatin-Based Chemoresistant Biomarkers in Colorectal Adenocarcinoma

Circulating MiR-125b As a Marker Predicting Chemoresistance in Breast Cancer

Plasma Micrornas to Predict the Response of Radiotherapy in Esophageal Squamous Cell Carcinoma Patients.

Plasma Microrna Signatures to Predict Egfr-Tki Resistance in Egfr-Mutant Advanced Nsclc Patients.

Evaluation of Plasma Microrna Levels to Predict Insensitivity of Patients with Advanced Lung Adenocarcinomas to Pemetrexed and Platinum

MiRNA signature predicts the response of patients with advanced lung adenocarcinoma to platinum-based treatment

A panel of serum exosomal microRNAs as predictive markers for chemoresistance in advanced colorectal cancer

Plasma‐based Microrna Signatures in Early Diagnosis of Breast Cancer

Potential biomarkers as a predictive factor of response to primary chemotherapy in breast cancer patients

Plasma Mir-324-3p and Mir-1285 As Diagnostic and Prognostic Biomarkers for Early Stage Lung Squamous Cell Carcinoma

Plasma MicroRNA Pair Panels As Novel Biomarkers for Detection of Early Stage Breast Cancer

Circulating microRNAs as indicators in the prediction of neoadjuvant chemotherapy response in luminal B breast cancer

Plasma CAMK2A Predicts Chemotherapy Resistance in Metastatic Triple Negative Breast Cancer